Companies looking to scale DNA production from discovery to clinical development without the usual delays and safety risks now have a better-funded partner. NunaBio Limited, a next-generation CDMO, has raised $8.8M to advance its universal, cell-free DNA solutions.
The company's offering centers on disposable, SaaS-controlled hardware units that enable DNA production for applications from therapies to advanced materials. This innovative system significantly reduces the space required compared to traditional methods, allowing researchers and manufacturers to move seamlessly through development stages.














